Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Glycine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.36 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.36 |
| ▸ | OR51E2 | Q9H255 | 2/20 | 0.59 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.59 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.59 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.43 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.36 |
| ▸ | PPARG | P37231 | 7/20 | 0.36 |
| ▸ | PPARD | Q03181 | 7/20 | 0.36 |
| ▸ | PPARA | Q07869 | 7/20 | 0.36 |
| ▸ | HDAC11 | Q96DB2 | 6/20 | 0.36 |
| ▸ | TSHR | P16473 | 5/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycine SCHEMBL2231959 | 0.91 | — | — | |
| Glycine SCHEMBL7102795 | 0.87 | — | — | |
| Glycine SCHEMBL781340 | 0.85 | OR51E2 (0.62) | OR51E2GLRA1SLC6A9FFAR3HDAC3 | |
| Glycine SCHEMBL28072442 | 0.81 | — | — | |
| Glycine SCHEMBL10378304 | 0.81 | GLRA1 (0.67) | OR51E2GLRA1SLC6A9FFAR3HDAC3 | |
| Glycine SCHEMBL10378302 | 0.81 | GLRA1 (0.67) | OR51E2GLRA1SLC6A9FFAR3HDAC3 | |
| Glycine SCHEMBL2361724 | 0.81 | — | — | |
| Glycine SCHEMBL28449741 | 0.81 | — | — | |
| Glycine SCHEMBL2687281 | 0.79 | — | — | |
| Pentane SCHEMBL9057930 | 0.79 | OR51E2 (0.62) | OR51E2GLRA1SLC6A9FFAR3HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040180910-A1 | Heterocycle carboxamides as antiviral agents | SCHNUTE MARK E (US) | 2004-09-16 | — | — | US | disclosed |
| US-6730682-B2 | HERPES VIRUS | PHARMACIA & UPJOHN COMPANY | 2004-05-04 | — | — | US | disclosed |
| EP-1363907-A2 | HETEROCYCLE CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-11-26 | — | — | EP | disclosed |
| US-20020019397-A1 | Heterocycle carboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-02-14 | — | — | US | disclosed |
| WO-2002004443-A2 | HETEROCYCLE CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180910-A1 | Heterocycle carboxamides as antiviral agents | ZC3HAV1, ZC3HAV1L, HDAC1 | PDE4A 2735/4885PDE3A 2450/4885OR51E2 3539/4885 |
| US-20020019397-A1 | Heterocycle carboxamides as antiviral agents | ZC3HAV1, ZC3HAV1L, HDAC1 | PDE4A 2735/4885PDE3A 2450/4885OR51E2 3539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.